Skip to main content
Vishal C Patel

Dr Vishal C Patel

Consultant Hepatologist (KCH); Principal Investigator (FLR); Adjunct Reader in Hepatology (KCL)

Biography

Vishal Patel is a Consultant Hepatologist & Endoscopist at the Liver Unit, King’s College Hospital, having been involved in the inception of the Advanced Chronic Liver Disease (ACLD) service and managing complications related to portal hypertension. He is a Principal Investigator and Group Lead for ACLD Patho-Biology & Therapeutics with his research group based at the Roger Williams Institute of Hepatology, and is an Adjunct Reader in Hepatology within the School of Immunology & Microbial Sciences at King’s College London.

His laboratory group focuses on translational research on the oral-gut-liver axis in cirrhosis, evolving from his doctorate research, and infection-related complications that patients with ACLD face their exposure, in an era of ever-escalating threats from antimicrobial resistance. His group is now focused on metagenomic profiling with primary interests based around characterising and understanding the pathophysiological role of the microbiome in driving chronic liver failure syndromes, and non-antimicrobial-based therapeutic interventions that can more effectively target oral-gut dysbiosis, pathological bacterial translocation and immune dysfunction.

Linked to this is the ‘Rapid Infection Diagnostics in Cirrhosis’ (RIDiC) study evaluating the role of novel sequencing-based approaches as a means to combat AMR, in industry collaboration with Oxford Nanopore Technologies. His group have active works-streams exploring the role of circulating cell-free DNA (cfDNA) and coagulation dysfunction in chronic liver failure syndromes where epigenetic profiling of cfDNA is being used as a novel approach via the concept of ‘liquid biopsy’ to assess covert organ dysfunction.

He is Chief Investigator of the NIHR HTA-funded £2.5 million BOPPP trial (ClinicalTrials.gov ID: NCT03776955) evaluating the effectiveness of non-selective beta-blockers to prevent hepatic decompensation in patients with small oesophageal varices and cirrhosis. BOPPP is currently the largest portal hypertension trial globally, and successfully surpassed the recruitment target of 740 patients across 55 UK sites in July 2024.

Vishal is involved in several observational and interventional studies in chronic liver failure syndromes, including acute alcohol-related hepatitis, hepatic encephalopathy, and faecal microbial transplantation in cirrhosis. He has extensive study set up and trial delivery experience and expertise, having also been involved in the interventional trial portfolio during the COVID19 pandemic. He is the Liver Research Delivery Unit Clinical Lead at King's College Hospital, overseeing one of the largest trial portfolios of non-commercial and commercial studies in Europe.

“Chronic liver disease is a condition which I am dedicated to treating clinically and still represents so much unmet need. Translational research in this area is pivotal to improving patient outcomes and quality of life in those that are afflicted. My group in collaboration with others are determined to make real progress in this area."

You can find more information about Vishal's publications and work with the following links:

Currently working on

The ACLD Experimental & Therapeutics group based at the Roger Williams Institute of Hepatology actively collaborates with clinical, translational and basic science groups as well as industry and biotech. Research work-streams are focused on advanced chronic liver disease (ACLD) to better understand (i) patho-biological pathways and disease mechanisms, and (ii) to develop novel diagnostics and (iii) therapeutic interventions:

  1. The oral-gut-liver axis in ACLD:
  • Interrogating oral and gut micro-/mycobiome and viromic functional alterations utilising metagenomic sequencing
  • Intestinal barrier dysfunction in cirrhosis:
    • PhD studentship, co-supervising with Prof Shilpa Chokshi (University of Plymouth)
  • Non-antibiotic based therapeutics targeting the oral-gut-liver axis – pre-clinical development and in-human trials.
  1. Rapid Infection Diagnostics in Cirrhosis (RIDiC):
  • Clinical metagenomic approaches including antimicrobial resistance evaluation, co-led by Dr Merianne Mohamed (post-doctoral scientist)
    • PhD studentship, co-supervising with Prof Jessica Blair (University of Birmingham)
  1. Coagulation dysfunction and role of cell-free DNA:
  • Cell-free DNA profiling in ACLD (and acute liver failure syndromes)
  • Coagulation, immune-inflammatory and haemostasis pathway interrogation (collaboration with Prof Ton Lisman, Netherlands)
  • Epigenetic approaches to study organ dysfunction
    • PhD studentship commencing Feb 2025.

This research is resourced by a combination of (inter)national grants and funding and involves well established collaborations with research groups across King’s Health Partners, within London and the UK, and working with international partners based in Denmark, Germany, Spain, Sweden, North America and Australia.

Teaching

  • Vishal is a teacher on the course: Microbiome in Health & Disease MSc